Aflibercept

What is Aflibercept?

Aflibercept is a sophisticated pharmaceutical agent primarily used in ophthalmology to treat various serious eye conditions. It is a recombinant fusion protein, meaning it's engineered in a lab to combine parts of different proteins. Marketed under brand names such as Eylea, it functions as an anti-Vascular Endothelial Growth Factor (VEGF) agent. VEGF is a naturally occurring protein in the body that plays a crucial role in the formation of new blood vessels. In certain eye diseases, an overproduction of VEGF leads to abnormal and leaky blood vessels, which can severely impair vision. Aflibercept is designed to counteract this process, thereby preserving and often improving visual acuity for patients suffering from these debilitating conditions.

How Does it Work?

The mechanism of action for Aflibercept is quite unique and highly effective. It acts as a 'VEGF trap' by binding to and inhibiting the activity of several growth factors, including VEGF-A, VEGF-B, and placental growth factor (PlGF). These growth factors are key promoters of angiogenesis, the process of forming new blood vessels, and increased vascular permeability, which causes fluid leakage. In retinal diseases, excessive VEGF leads to abnormal blood vessel growth, a process known as neovascularization, and fluid accumulation (edema) in the macula, the central part of the retina responsible for sharp, detailed vision. By trapping these growth factors, Aflibercept prevents them from binding to their receptors on endothelial cells, which are the cells lining blood vessels. This action effectively stops the growth of new, leaky blood vessels and reduces fluid leakage, thereby limiting damage to the retina and improving the ocular environment. Its high affinity for VEGF makes it a potent and long-lasting treatment option.

Medical Uses

Aflibercept is approved for the treatment of several sight-threatening eye conditions, all characterized by abnormal blood vessel growth or leakage in the retina:

• Wet age-related macular degeneration (wet AMD)

  This is a leading cause of severe vision loss in older adults, where abnormal blood vessels grow under the retina and leak blood and fluid, damaging the macula.

• Diabetic macular edema (DME)

  A common complication of diabetes, DME occurs when high blood sugar damages blood vessels in the retina, causing them to leak fluid into the macula, leading to swelling and blurred vision.

• Macular edema secondary to retinal vein occlusion (RVO)

  RVO involves a blockage in one of the veins carrying blood away from the retina, leading to blood and fluid leakage, and subsequent macular swelling. Aflibercept is used for both central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).

• Diabetic retinopathy (DR) with DME

  Aflibercept is also used to treat diabetic retinopathy, especially when accompanied by macular edema, to prevent further progression of the disease and preserve vision.

These conditions can lead to irreversible vision loss if left untreated, making Aflibercept a critical therapeutic option.

Dosage

Aflibercept is administered as an intravitreal injection, meaning it is injected directly into the vitreous humor (the gel-like substance that fills the eye) by a qualified ophthalmologist. The typical dosage for most conditions is 2 mg per eye. The frequency of injections varies depending on the specific condition and the patient's response to treatment. For example, in wet AMD, initial treatment often involves monthly injections for a few months, followed by extended intervals, such as every two months, or a 'treat-and-extend' regimen where the interval between injections is gradually increased as long as the disease remains stable. For DME and RVO, similar regimens may apply. The exact dosing schedule is determined by the treating physician based on regular monitoring of the patient's eye health and visual acuity.

Side Effects

While generally well-tolerated, Aflibercept injections can cause side effects. Most common side effects are usually mild and related to the injection procedure itself:

• Eye pain or discomfort
• Conjunctival hemorrhage (redness in the white of the eye)
• Vitreous floaters (small spots or specks that drift across the field of vision)
• Increased intraocular pressure
• Temporary blurred vision

More serious, though rare, side effects can occur. These include:

• Endophthalmitis (a severe infection inside the eye)
• Retinal detachment
• Cataract formation or progression
• Vitreous hemorrhage (bleeding in the vitreous)
• Serious allergic reactions
• Arterial thromboembolic events (e.g., stroke, heart attack), although the systemic risk is generally low due to local administration.

Patients should always discuss potential risks and benefits with their healthcare provider and report any unusual or severe symptoms immediately after an injection.

Drug Interactions

Due to its local administration directly into the eye, systemic drug interactions with Aflibercept are considered minimal. The amount of Aflibercept that reaches the bloodstream is very low, reducing the likelihood of interactions with other medications taken orally or intravenously. However, it is always important to inform your ophthalmologist about all prescription and over-the-counter medications, vitamins, and herbal supplements you are currently taking. While not typically co-administered, the use of other anti-VEGF agents or other ophthalmic medications should be disclosed to avoid potential additive effects or contraindications.

FAQ

What is Eylea?

Eylea is a prominent brand name for the medication Aflibercept, specifically used for ophthalmic conditions.

How long does Aflibercept last?

The effects of an Aflibercept injection typically last for several weeks to a few months, depending on the individual and the condition being treated. This allows for extended dosing intervals compared to some other treatments.

Is Aflibercept a cure for eye conditions?

No, Aflibercept is not a cure. It is a treatment that manages the progression of eye diseases like wet AMD, DME, and RVO by inhibiting abnormal blood vessel growth and leakage, thereby preserving or improving vision.

What should I avoid after an Aflibercept injection?

Patients are generally advised to avoid rubbing their eyes, swimming, or engaging in strenuous activities for a few days after an injection to minimize the risk of infection or complications.

Can Aflibercept improve vision?

Yes, many patients experience stabilization of vision, and some achieve significant improvement in visual acuity, especially if treatment is initiated early.

Products containing Aflibercept are available through trusted online pharmacies. You can browse Aflibercept-based medications at ShipperVIP or Medicenter.

Summary

Aflibercept stands as a cornerstone in the treatment of several severe retinal diseases, including wet AMD, DME, and RVO. By effectively neutralizing key growth factors like VEGF, it prevents the formation of damaging new blood vessels and reduces fluid leakage, which are primary causes of vision loss. Administered via intravitreal injection, its targeted action offers significant benefits in preserving and improving ocular health. While generally safe, patients should be aware of potential side effects and maintain open communication with their ophthalmologist. As an advanced anti-VEGF therapy, Aflibercept continues to offer hope and improved quality of life for countless individuals facing challenging eye conditions.